Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.34 |
| ▸ | BCL2 | P10415 | 7/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23065722 | 0.95 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2AMAPTFNTA | |
| SCHEMBL23065415 | 0.82 | MEN1 (0.38) | ALDH1A1MEN1KMT2AMAPTFNTA | |
| SCHEMBL13858558 | 0.81 | FNTA (0.43) | ALDH1A1MEN1KMT2AMAPTFNTA | |
| SCHEMBL13858559 | 0.81 | FNTA (0.43) | ALDH1A1MEN1KMT2AMAPTFNTA | |
| SCHEMBL23065403 | 0.74 | OPRM1 (0.38) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23042712 | 0.73 | ALDH1A1 (0.33) | ALDH1A1ALOX15 | |
| SCHEMBL3971638 | 0.73 | MEN1 (0.45) | ALDH1A1MEN1KMT2AMAPTFNTA | |
| SCHEMBL19994535 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AMAPTFNTA | |
| SCHEMBL28451811 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2AMAPTFNTA | |
| SCHEMBL21609550 | 0.72 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AMAPTFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | UNM RAINFOREST INNOVATIONS | 2023-02-09 | — | — | US | disclosed |
| WO-2021041107-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 | UNM RAINFOREST INNOVATIONS (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | GPER1, GPR35, GPR34 | ALDH1A1 1983/4885MEN1 921/4885KMT2A 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.